Blurbs

Analysts Offer Insights on Healthcare Companies: Amarin (AMRN), Insmed (INSM) and MannKind (MNKD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (AMRNResearch Report), Insmed (INSMResearch Report) and MannKind (MNKDResearch Report) with bullish sentiments.

Amarin (AMRN)

In a report issued on March 28, Roanna Ruiz from Leerink Partners reiterated a Buy rating on Amarin, with a price target of $10.00. The company’s shares closed last Tuesday at $3.38, close to its 52-week low of $2.76.

According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.5% and a 36.0% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.

Currently, the analyst consensus on Amarin is a Moderate Buy with an average price target of $9.50, which is a 190.5% upside from current levels. In a report issued on March 15, Piper Sandler also maintained a Buy rating on the stock with a $19.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Insmed (INSM)

In a report issued on March 28, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Insmed. The company’s shares closed last Tuesday at $23.19.

According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.6% and a 35.0% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.

Insmed has an analyst consensus of Strong Buy, with a price target consensus of $48.80.

MannKind (MNKD)

Leerink Partners analyst Thomas Smith reiterated a Buy rating on MannKind on March 28. The company’s shares closed last Tuesday at $3.81.

According to TipRanks.com, Smith is ranked 0 out of 5 stars with an average return of -16.6% and a 28.0% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Prometheus Biosciences.

Currently, the analyst consensus on MannKind is a Strong Buy with an average price target of $6.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos